GTC 6000
Alternative Names: GTC-6000Latest Information Update: 28 Jul 2025
At a glance
- Originator Gismo Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action Glycosaminoglycan modulators; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease; Frontotemporal dementia; Tauopathies
Most Recent Events
- 28 Jul 2025 GTC 6000 is still in early research for Alzheimer's disease, Frontotemporal dementia, Tauopathies in USA (PO) (Gismo Therapeutics pipeline, July 2025)
- 28 Jul 2025 GTC 6000 is available for licensing as of 28 Jul 2025. https://gismotherapeutics.com/investors/
- 14 Jun 2019 Gismo Therapeutics plans IND-enabling studies for Alzheimer's disease, Frontotemporal dementia and Tauopathies in USA (PO) (Gismo Therapeutics pipeline, July 2025)